[	O
The	O
erbB	O
gene	O
family	O
:	O
significance	O
for	O
tumor	B-Cancer
development	O
,	O
prognosis	O
and	O
new	O
therapeutic	O
modalities	O
]	O
.	O

RNA	O
and	O
DNA	O
viruses	O
can	O
be	O
transforming	O
and	O
tumourigenic	O
agents	O
.	O

The	O
transformation	O
is	O
a	O
consequence	O
of	O
the	O
ability	O
of	O
viruses	O
to	O
integrate	O
into	O
the	O
host	O
cell	B-Cell
'	O
s	O
DNA	O
and	O
to	O
produce	O
transforming	O
proteins	O
.	O

These	O
proteins	O
are	O
mainly	O
produced	O
by	O
specific	O
integral	O
parts	O
of	O
the	O
viral	O
genome	O
,	O
the	O
oncogenes	O
.	O

Comparison	O
between	O
RNA	O
/	O
DNA	O
sequence	O
of	O
viral	O
oncogenes	O
and	O
normal	O
human	O
genome	O
of	O
non	O
-	O
transformed	O
cells	B-Cell
revealed	O
high	O
sequence	O
similarities	O
in	O
specific	O
genomic	O
areas	O
,	O
which	O
were	O
named	O
cellular	B-Cell
proto	O
-	O
oncogens	O
.	O

They	O
are	O
important	O
components	O
of	O
the	O
growth	O
regulatory	O
pathways	O
in	O
normal	O
cells	B-Cell
.	O

The	O
accumulation	O
of	O
genetic	O
alterations	O
of	O
some	O
proto	O
-	O
oncogens	O
,	O
like	O
the	O
erbB	O
-	O
family	O
,	O
may	O
be	O
part	O
of	O
the	O
mechanism	O
,	O
by	O
which	O
malignant	B-Cell
cells	I-Cell
can	O
acquire	O
a	O
selective	O
growth	O
advantage	O
.	O

The	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGF	O
-	O
R	O
,	O
c	O
-	O
erbB1	O
)	O
,	O
Her	O
-	O
2	O
/	O
neu	O
(	O
c	O
-	O
erbB2	O
)	O
,	O
and	O
c	O
-	O
erbB3	O
are	O
members	O
of	O
the	O
erbB	O
-	O
family	O
.	O

The	O
detection	O
of	O
increased	O
abundance	O
of	O
EGF	O
-	O
R	O
or	O
Her	O
-	O
2	O
/	O
neu	O
proteins	O
in	O
human	O
tumours	B-Cancer
can	O
provide	O
additional	O
information	O
on	O
the	O
disease	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
for	O
patients	O
with	O
breast	B-Cancer
,	O
ovarian	B-Cancer
,	O
endometrial	B-Cancer
or	O
cervical	B-Cancer
cancer	I-Cancer
.	O

Molecular	O
and	O
cell	B-Cell
-	O
physiological	O
analyses	O
have	O
improved	O
the	O
understanding	O
of	O
tumour	B-Cancer
biology	O
and	O
provide	O
the	O
opportunity	O
for	O
new	O
therapeutic	O
approaches	O
.	O

Monoclonal	O
antibody	O
targeted	O
therapy	O
directed	O
against	O
EGF	O
-	O
R	O
or	O
Her	O
-	O
2	O
/	O
neu	O
,	O
the	O
use	O
of	O
anti	O
-	O
sense	O
oligonucleotides	O
and	O
oligodeoxynucleotides	O
,	O
and	O
the	O
application	O
of	O
tyrosine	O
kinase	O
and	O
protein	O
C	O
-	O
kinase	O
inhibitors	O
are	O
currently	O
being	O
investigated	O
.	O

